Immunological approaches to nicotine addiction

Paul Pentel, Mark LeSage, Daniel E. Keyler, Dorothy Hatsukami

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


Vaccines for the treatment of drug addiction differ from available medications in that they target the drug rather than the brain. Vaccination against nicotine elicits the production of nicotine-specific antibodies which bind nicotine, reduce and slow nicotine distribution to brain, and slow nicotine elimination. Vaccination of rats attenuates a variety of behaviors relevant to addiction, including nicotine discrimination and nicotine self-administration. Early clinical trials have confirmed vaccine safety and immunogenicity, and some measures suggest that vaccination may reduce smoking and improve cessation rates. Potential advantages of vaccination include its long duration of action and its unique mechanisms, which may expand the range of effects achievable with medication or provide added efficacy when combined with medications that act through complementary mechanisms. Challenges include reliably producing sufficient antibody levels and the possibility that vaccinated smokers could increase their smoking to compensate for the binding of nicotine.

Original languageEnglish (US)
Title of host publicationMedication Treatments for Nicotine Dependence
PublisherCRC Press
Number of pages16
ISBN (Electronic)9781420005431
ISBN (Print)0849337798, 9780849337796
StatePublished - Jan 1 2006

Bibliographical note

Publisher Copyright:
© 2007 by Taylor & Francis Group, LLC.


Dive into the research topics of 'Immunological approaches to nicotine addiction'. Together they form a unique fingerprint.

Cite this